rise < risk < rituximab

Facettes : Author.f AffPays.f AffRegion.f AffVille.f AffOrg.f Mesh.f MeshFr.f Teeft.f

List of bibliographic references

Number of relevant bibliographic references: 23.
[0-20] [0 - 20][0 - 23][20-22][20-40]

Ident.	Authors (with country if any)	Title
000093 (2020)	Yuan-Yang Cheng [Taïwan] ; Shin-Tsu Chang [Taïwan] ; Chung-Lan Kao [Taïwan] ; Yi-Huei Chen [Taïwan] ; Ching-Heng Lin [Taïwan]	The impact of rehabilitation frequency on the risk of stroke in patients with rheumatoid arthritis
000118 (2020)	Gregory S. Calip [États-Unis] ; Pritesh R. Patel [États-Unis] ; Karen Sweiss [États-Unis] ; Zhaoju Wu [États-Unis] ; Jifang Zhou [États-Unis] ; Alemseged A. Asfaw [États-Unis] ; Sruthi Adimadhyam [États-Unis] ; Todd A. Lee [États-Unis] ; Brian C-H Chiu [États-Unis]	Targets of biologic disease-modifying antirheumatic drugs and risk of multiple myeloma.
000120 (2020)	Boghuma Titanji ; Christina Gavegnano ; Priscilla Hsue ; Raymond Schinazi ; Vincent C. Marconi	Targeting Inflammation to Reduce Atherosclerotic Cardiovascular Risk in People With HIV Infection
000159 (2020)	Cem Gabay [Suisse] ; Gerd R. Burmester [Allemagne] ; Vibeke Strand [États-Unis] ; Jérôme Msihid [France] ; Moshe Zilberstein [États-Unis] ; Toshio Kimura [États-Unis] ; Hubert Van Hoogstraten [États-Unis] ; Susan H. Boklage [États-Unis] ; Jonathan Sadeh [États-Unis] ; Neil M. H. Graham [États-Unis] ; Anita Boyapati [États-Unis]	Sarilumab and adalimumab differential effects on bone remodelling and cardiovascular risk biomarkers, and predictions of treatment outcomes
000183 (2020)	Ibai Los-Arcos [Espagne] ; Juan Aguilar-Company [Espagne] ; Isabel Ruiz-Camps [Espagne]	Risk of infection associated with new therapies for lymphoproliferative syndromes.
000184 (2020)	Maria C. Schneeweiss [États-Unis] ; Seoyoung C. Kim [États-Unis] ; Sebastian Schneeweiss [États-Unis] ; David Rosmarin [États-Unis] ; Joseph F. Merola [États-Unis]	Risk of Inflammatory Arthritis After a New Diagnosis of Hidradenitis Suppurativa
000185 (2020)	Yuan-Yuan Wei [République populaire de Chine] ; Rui-Rui Wang [République populaire de Chine] ; Da-Wei Zhang [République populaire de Chine] ; You- Hui Tu [République populaire de Chine] ; Chang- Shan Chen [République populaire de Chine] ; Shuang Ji [République populaire de Chine] ; Chun-Xi Li [République populaire de Chine] ; Xiu-Yong Li [République populaire de Chine] ; Meng-Xi Zhou [République populaire de Chine] ; Wen- Sheng Cao [République populaire de Chine] ; Ming- Feng Han [République populaire de Chine] ; Guang-He Fei [République populaire de Chine]	Risk factors for severe COVID-19: evidence from 167 hospitalized patients in Anhui, China
000186 (2020)	Xin Xu ; Hai-Chang Dong ; Zheng Yao ; Yun-Zhao Zhao	Risk factors for postoperative sepsis in patients with gastrointestinal perforation
000189 (2020)	Anastasia Vishnevetsky [États-Unis] ; Michael Levy [États-Unis]	Rethinking high-risk groups in COVID-19
000206 (2020)	Christos Koutsianas ; Konstantinos Thomas ; Dimitrios Vassilopoulos	Reactivation of hepatitis B virus infection in rheumatic diseases: risk and management considerations
000216 (2020)	Elaheh Kordzadeh-Kermani [Iran] ; Hossein Khalili [Iran] ; Iman Karimzadeh [Iran] ; Mohammadreza Salehi [Iran]	Prevention Strategies to Minimize the Infection Risk Associated with Biologic and Targeted Immunomodulators
000269 (2020)	Jose Manuel Sánchez-Maldonado [Espagne] ; Manuel Martínez-Bueno [Espagne] ; Helena Canhão [Portugal] ; Rob Ter Horst [Pays-Bas] ; Sonia Mu Oz-Pe A [Espagne] ; Ana Mo Iz-Díez [Espagne] ; Ana Rodríguez-Ramos [Espagne] ; Alejandro Escudero [Espagne] ; Signe B. Sorensen [Danemark] ; Merete L. Hetland [Danemark] ; Miguel A. Ferrer [Espagne] ; Bente Glintborg [Danemark] ; Ileana Filipescu [Roumanie] ; Eva Pérez-Pampin [Espagne] ; Pablo Conesa-Zamora [Espagne] ; Antonio García [Espagne] ; Alfons Den Broeder [Pays-Bas] ; Salvatore De Vita [Italie] ; Svend Erik Hove Jacobsen [Danemark] ; Eduardo Collantes [Espagne] ; Luca Quartuccio [Italie] ; Mihai G. Netea [Pays-Bas, Allemagne] ; Yang Li [Pays-Bas] ; João E. Fonseca [Portugal] ; Manuel Jurado [Espagne] ; Miguel Ngel L Pez-Nevot [Espagne] ; Marieke J. H. Coenen [Pays-Bas] ; Vibeke Andersen [Danemark] ; Rafael Cáliz [Espagne] ; Juan Sainz [Espagne]	NFKB2 polymorphisms associate with the risk of developing rheumatoid arthritis and response to TNF inhibitors: Results from the REPAIR consortium
000274 (2020)	Meng Hsuan Kuo [Taïwan] ; Chih-Wei Tseng [Taïwan] ; Chi-Hui Lee [Taïwan] ; Chien-Hsueh Tung [Taïwan] ; Kuo-Chih Tseng [Taïwan] ; Ning-Sheng Lai [Taïwan]	Moderate Risk of Hepatitis B Virus Reactivation in HBsAg−/HBcAb+ Carriers Receiving Rituximab for Rheumatoid Arthritis
000332 (2020)	Ying-Ming Chiu [Taïwan] ; Der-Yuan Chen [Taïwan]	Infection risk in patients undergoing treatment for inflammatory arthritis: non-biologics versus biologics.
000334 (2020)	Amin Gasmi [France] ; Sadaf Noor [Pakistan] ; Torsak Tippairote [Thaïlande] ; Maryam Dadar [Iran] ; Alain Menzel [France] ; Geir Bj Rklund [Norvège]	Individual risk management strategy and potential therapeutic options for the COVID-19 pandemic
000393 (2020)	Dinesh Khanna ; Donald P. Tashkin ; Christopher P. Denton ; Elisabetta A. Renzoni ; Sujal R. Desai ; John Varga	Etiology, Risk Factors, and Biomarkers in Systemic Sclerosis with Interstitial Lung Disease
000439 (2020)	L. Baganz [Allemagne] ; J. Listing [Allemagne] ; J. Kekow [Allemagne] ; C. Eisterhues [Allemagne] ; S. Wassenberg [Allemagne] ; A. Zink [Allemagne] ; A. Strangfeld [Allemagne]	Different risk profiles of biologic agents for new-onset psoriasis in patients with rheumatoid arthritis.
000471 (2020)	Giuseppe Di Lorenzo [Italie] ; Rossella Di Trolio [Italie]	Coronavirus Disease (COVID-19) in Italy: Analysis of Risk Factors and Proposed Remedial Measures
000486 (2020)	Rishi J. Desai ; Sara Dejene ; Yinzhu Jin ; Jun Liu ; Seoyoung C. Kim	Comparative Risk of Diabetes Mellitus in Patients With Rheumatoid Arthritis Treated With Biologic or Targeted Synthetic Disease‐Modifying Drugs: A Cohort Study
000487 (2020)	Siddharth Singh ; Mathurin Fumery [France] ; Abha G. Singh ; Namrata Singh [États-Unis] ; Larry J. Prokop [États-Unis] ; Parambir S. Dulai ; William J. Sandborn ; Jeffrey R. Curtis	Comparative Risk of Cardiovascular Events With Biologic and Synthetic Disease-Modifying Antirheumatic Drugs in Patients With Rheumatoid Arthritis: A Systematic Review and Meta-Analysis.
000530 (2020)	Georg Schett [Allemagne] ; Michael Sticherling [Allemagne] ; Markus F. Neurath [Allemagne]	COVID-19: risk for cytokine targeting in chronic inflammatory diseases?

---

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/2020/Analysis

HfdIndexSelect -h $EXPLOR_AREA/Data/2020/Analysis/Title.i -k "risk" 

HfdIndexSelect -h $EXPLOR_AREA/Data/2020/Analysis/Title.i  \
                -Sk "risk" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/2020/Analysis/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    TocilizumabV1
   |flux=    2020
   |étape=   Analysis
   |type=    indexItem
   |index=    Title.i
   |clé=    risk
}}

---

This area was generated with Dilib version V0.6.34. Data generation: Fri May 22 09:34:00 2020. Site generation: Sun Mar 28 09:01:19 2021